Power to the Patients
Why Neuroscience Trials Keep Failing and What Could Fix Them
November 5, 2026
Neuroscience trials often enroll hundreds of patients, run for years, and still end without a clear answer. Some researchers now think a small study with the right measures can tell you more than a large one. In this episode of Power to the Patients, Brandon Li brings together Craig Erickson, Chief Medical Advisor at Spinogenix, and Gabriel Vargas, Chief Medical Officer at CuraSen Therapeutics, to look at why these drugs are so hard to develop and what could work better. They cover what anti-amyloid antibodies do and do not deliver in Alzheimer’s, why synapses sit at the center of so many brain disorders, and what patients and investors should watch next.

Neuroscience has one of the toughest track records in drug development. Large trials enroll hundreds of patients, struggle with placebo response, and often end with teams chasing subgroups in secondary endpoints. In this episode of Power to the Patients, host Brandon Li speaks with two experts who approach the problem from different angles.


Craig Erickson, a Psychiatrist at Cincinnati Children's and Chief Medical Advisor at Spinogenix, explains how high-density EEG, transcranial magnetic stimulation, and computer-based cognitive testing can show whether a drug is doing anything at all.


Gabriel Vargas, Chief Medical Officer at CuraSen Therapeutics, shares his view of the amyloid hypothesis he once believed in, the gap between biomarker results and patient benefit, and how CuraSen reaches the brain's adrenergic system without the usual effects on the heart and metabolism.


What You’ll Learn:


About the Guests

Craig Erickson, MD, is a child and adolescent Psychiatrist at Cincinnati Children's Hospital Medical Center, where he directs the Cincinnati Fragile X Research and Treatment Center.

He is also Chief Medical Advisor at Spinogenix and was principal investigator of the Phase 2 study of SPG601 in Fragile X syndrome (FXS).

After years of negative autism trials, his work now centers on quantitative, placebo-resistant measures of brain function to guide early decisions in drug development.

Gabriel Vargas, MD, PhD, is Chief Medical Officer at CuraSen Therapeutics, which develops oral small molecules that act on the brain's adrenergic system for psychiatric and neurodegenerative diseases.

Before CuraSen, he was neuroscience therapeutic area head for early development at Amgen, where he led early development of Aimovig and oversaw digital health.

Gabriel also serves on the editorial board of the journal Digital Biomarkers.



Episode Resources